- Home
- BNRG vs CDIO Comparison
BNRG vs CDIO Comparison
Compare BNRG & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNRG
- CDIO
- Stock Information
- Founded
- BNRG 2012
- CDIO 2017
- Country
- BNRG Israel
- CDIO United States
- Employees
- BNRG N/A
- CDIO N/A
- Industry
- BNRG
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- BNRG
- CDIO Health Care
- Exchange
- BNRG Nasdaq
- CDIO Nasdaq
- Market Cap
- BNRG 6.2M
- CDIO 6.4M
- IPO Year
- BNRG 2022
- CDIO N/A
- Fundamental
- Price
- BNRG N/A
- CDIO N/A
- Analyst Decision
- BNRG
- CDIO
- Analyst Count
- BNRG 0
- CDIO 0
- Target Price
- BNRG N/A
- CDIO N/A
- AVG Volume (30 Days)
- BNRG 343.5K
- CDIO 40.0K
- Earning Date
- BNRG 09-30-2025
- CDIO 11-12-2025
- Dividend Yield
- BNRG N/A
- CDIO N/A
- EPS Growth
- BNRG N/A
- CDIO N/A
- EPS
- BNRG N/A
- CDIO N/A
- Revenue
- BNRG $387,000.00
- CDIO $19,507.00
- Revenue This Year
- BNRG N/A
- CDIO $1,434.82
- Revenue Next Year
- BNRG N/A
- CDIO $4,661.91
- P/E Ratio
- BNRG N/A
- CDIO N/A
- Revenue Growth
- BNRG 843.90
- CDIO N/A
- 52 Week Low
- BNRG $1.50
- CDIO $3.22
- 52 Week High
- BNRG $15.30
- CDIO $53.10
- Technical
- Relative Strength Index (RSI)
- BNRG 36.62
- CDIO 58.63
- Support Level
- BNRG $1.55
- CDIO $4.16
- Resistance Level
- BNRG $1.74
- CDIO $4.63
- Average True Range (ATR)
- BNRG 0.16
- CDIO 0.33
- MACD
- BNRG -0.06
- CDIO 0.03
- Stochastic Oscillator
- BNRG 7.45
- CDIO 56.28
About BNRG Brenmiller Energy Ltd
Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.